Antibody Responses after Additional COVID-19 Vaccines in Immunocompromised Persons

June 6, 2022

The Lancet recently conducted a literature review of antibody responses after COVID-19 vaccination in immunocompromised persons published between July 1, 2020, and September 27, 2021. Authors aggregated information from 23 studies with a total of 1722 persons who received an additional dose of a COVID-19 vaccine due to their immunocompromised status.

Of the 23 studies included in the review, 18 exclusively offered mRNA vaccines, versus 2 offering AstraZeneca or Johnson & Johnson as additional doses after an mRNA primary series. Additional doses were administered 1-3 months after a primary series in 20 studies. Overall, seroconversion rates (method of assessing vaccine efficacy) after two COVID-19 vaccine doses were 99% for immunocompetent persons, versus 78% for persons with immune-mediated inflammatory disorders.

“No studies reported on the efficacy or effectiveness of an additional COVID-19 vaccine dose among people who are immunocompromised.” That being said, studies stated that an additional dose “appeared to have a modest additive effect” on immunogenicity levels. Also, reactions after receiving an additional dose were consistent with reactogenicity profiles after the first and second doses. Persons who elicited a low or undetectable antibody response after a primary series were able to elicit a median antibody response rate of 44%. It is still unclear how long protection after a third dose lasts, although it is assumed that the benefits of a third dose “are likely to outweigh the risks on the basis of the available data.”

Join Our Community!Stay Informed. Stay Hopeful.

Sign up for periodic emails with resources, insights, and updates on autoimmune disease and living with chronic illness.